Vestal Point Capital LP Sells 205,000 Shares of Dianthus Therapeutics, Inc. (NASDAQ:DNTH)

Vestal Point Capital LP decreased its stake in Dianthus Therapeutics, Inc. (NASDAQ:DNTH) by 34.2% during the 3rd quarter, HoldingsChannel.com reports. The fund owned 395,000 shares of the company’s stock after selling 205,000 shares during the period. Vestal Point Capital LP’s holdings in Dianthus Therapeutics were worth $10,815,000 as of its most recent filing with the SEC.

Several other hedge funds have also added to or reduced their stakes in DNTH. Vanguard Group Inc. grew its stake in shares of Dianthus Therapeutics by 250.0% during the 1st quarter. Vanguard Group Inc. now owns 537,828 shares of the company’s stock worth $16,135,000 after acquiring an additional 384,182 shares during the period. Bank of New York Mellon Corp boosted its position in Dianthus Therapeutics by 860.5% during the second quarter. Bank of New York Mellon Corp now owns 80,935 shares of the company’s stock worth $2,095,000 after purchasing an additional 72,509 shares during the period. SG Americas Securities LLC increased its stake in shares of Dianthus Therapeutics by 104.0% in the third quarter. SG Americas Securities LLC now owns 8,839 shares of the company’s stock worth $242,000 after purchasing an additional 4,506 shares in the last quarter. Point72 Asia Singapore Pte. Ltd. raised its position in shares of Dianthus Therapeutics by 281.9% in the second quarter. Point72 Asia Singapore Pte. Ltd. now owns 39,504 shares of the company’s stock valued at $1,022,000 after purchasing an additional 29,159 shares during the period. Finally, American Century Companies Inc. lifted its stake in shares of Dianthus Therapeutics by 38.6% during the 2nd quarter. American Century Companies Inc. now owns 30,432 shares of the company’s stock valued at $788,000 after buying an additional 8,473 shares in the last quarter. Institutional investors own 47.53% of the company’s stock.

Dianthus Therapeutics Stock Down 0.1 %

Shares of Dianthus Therapeutics stock opened at $23.83 on Friday. The company has a fifty day moving average of $26.82 and a 200-day moving average of $26.59. Dianthus Therapeutics, Inc. has a 52-week low of $6.58 and a 52-week high of $33.77.

Dianthus Therapeutics (NASDAQ:DNTH) last issued its earnings results on Thursday, November 7th. The company reported ($0.74) EPS for the quarter, missing the consensus estimate of ($0.59) by ($0.15). The firm had revenue of $2.17 million during the quarter, compared to analysts’ expectations of $1.07 million. Dianthus Therapeutics had a negative return on equity of 21.68% and a negative net margin of 1,250.32%. Analysts predict that Dianthus Therapeutics, Inc. will post -2.61 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

DNTH has been the topic of a number of analyst reports. Wedbush lowered their target price on shares of Dianthus Therapeutics from $38.00 to $36.00 and set an “outperform” rating on the stock in a report on Friday, August 9th. Raymond James raised their price objective on shares of Dianthus Therapeutics from $51.00 to $56.00 and gave the company an “outperform” rating in a research report on Friday, November 8th. Oppenheimer boosted their price target on shares of Dianthus Therapeutics from $48.00 to $52.00 and gave the company an “outperform” rating in a research report on Monday, November 11th. Finally, HC Wainwright restated a “buy” rating and issued a $40.00 price objective on shares of Dianthus Therapeutics in a research report on Monday, November 11th. Eight analysts have rated the stock with a buy rating and two have assigned a strong buy rating to the company. According to MarketBeat.com, Dianthus Therapeutics has a consensus rating of “Buy” and an average target price of $46.43.

About Dianthus Therapeutics

Dianthus Therapeutics, Inc, a clinical-stage biotechnology company, develops complement therapeutics for patients with severe autoimmune and inflammatory diseases. It is developing DNTH103, a monoclonal antibody, which is in Phase 2 clinical trial, for the treatment of generalized myasthenia gravis, multifocal motor neuropathy, and chronic inflammatory demyelinating polyneuropathy.